Creative Planning
VRTX icon

Creative Planning’s Vertex Pharmaceuticals VRTX Stock Holding History

Creative Planning’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,000
Closed -$128K – 2473
2020
Q3 		$128K Buy
+1,000
New +$276K ﹤0.01% 1790
2020
Q1 		– Sell
-800
Closed -$63K – 2095
2019
Q4 		$63K Buy
+800
New +$162K ﹤0.01% 1801
2018
Q4 		– Sell
-500
Closed -$50K – 2118
2018
Q3 		$50K Buy
+500
New +$89K ﹤0.01% 1878

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Creative Planning's VRTX Position: Q2 2026 in Review

Creative Planning increased its Vertex Pharmaceuticals (VRTX) stake by 17% in Q2 2026, buying an estimated $8.04M and bringing the position to 127,672 shares worth $63.4M. The position accounts for 0.04% of the portfolio, ranked #203.

Creative Planning first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. 1,757 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Creative Planning held 127,672 shares of Vertex Pharmaceuticals worth $63.4M as of Q2 2026.
  • Creative Planning bought 18,148 Vertex Pharmaceuticals shares in Q2 2026, an estimated $8.04M.
  • Vertex Pharmaceuticals made up 0.04% of Creative Planning's portfolio in Q2 2026, its #203 holding.
  • Creative Planning first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • 1,757 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.